» Articles » PMID: 37480549

Follow-up of Liver Metastases: a Comparison of Deep Learning and RECIST 1.1

Overview
Journal Eur Radiol
Specialty Radiology
Date 2023 Jul 22
PMID 37480549
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To compare liver metastases changes in CT assessed by radiologists using RECIST 1.1 and with aided simultaneous deep learning-based volumetric lesion changes analysis.

Methods: A total of 86 abdominal CT studies from 43 patients (prior and current scans) of abdominal CT scans of patients with 1041 liver metastases (mean = 12.1, std = 11.9, range 1-49) were analyzed. Two radiologists performed readings of all pairs; conventional with RECIST 1.1 and with computer-aided assessment. For computer-aided reading, we used a novel simultaneous multi-channel 3D R2U-Net classifier trained and validated on other scans. The reference was established by having an expert radiologist validate the computed lesion detection and segmentation. The results were then verified and modified as needed by another independent radiologist. The primary outcome measure was the disease status assessment with the conventional and the computer-aided readings with respect to the reference.

Results: For conventional and computer-aided reading, there was a difference in disease status classification in 40 out of 86 (46.51%) and 10 out of 86 (27.9%) CT studies with respect to the reference, respectively. Computer-aided reading improved conventional reading in 30 CT studies by 34.5% for two readers (23.2% and 46.51%) with respect to the reference standard. The main reason for the difference between the two readings was lesion volume differences (p = 0.01).

Conclusions: AI-based computer-aided analysis of liver metastases may improve the accuracy of the evaluation of neoplastic liver disease status.

Clinical Relevance Statement: AI may aid radiologists to improve the accuracy of evaluating changes over time in metastasis of the liver.

Key Points: • Classification of liver metastasis changes improved significantly in one-third of the cases with an automatically generated comprehensive lesion and lesion changes report. • Simultaneous deep learning changes detection and volumetric assessment may improve the evaluation of liver metastases temporal changes potentially improving disease management.

Citing Articles

Systematic Review: AI Applications in Liver Imaging with a Focus on Segmentation and Detection.

Pomohaci M, Grasu M, Baicoianu-Nitescu A, Enache R, Lupescu I Life (Basel). 2025; 15(2).

PMID: 40003667 PMC: 11856300. DOI: 10.3390/life15020258.


Tumor therapeutics in the era of "RECIST": past, current insights, and future prospects.

Xu Z, Jiang G, Dai J Oncol Rev. 2024; 18:1435922.

PMID: 39493769 PMC: 11527623. DOI: 10.3389/or.2024.1435922.


Vascular liver segmentation: a narrative review on methods and new insights brought by artificial intelligence.

Chierici A, Lareyre F, Salucki B, Iannelli A, Delingette H, Raffort J J Int Med Res. 2024; 52(9):3000605241263170.

PMID: 39291427 PMC: 11418557. DOI: 10.1177/03000605241263170.


Artificial intelligence for response prediction and personalisation in radiation oncology.

Zwanenburg A, Price G, Lock S Strahlenther Onkol. 2024; 201(3):266-273.

PMID: 39212687 PMC: 11839704. DOI: 10.1007/s00066-024-02281-z.


The role of superior hemorrhoidal vein ectasia in the preoperative staging of rectal cancer.

Lucarelli N, Mirabile A, Maggialetti N, Morelli C, Calbi R, Bartoli S Front Oncol. 2024; 14:1356022.

PMID: 39161384 PMC: 11330806. DOI: 10.3389/fonc.2024.1356022.


References
1.
Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

2.
Litiere S, Isaac G, de Vries E, Bogaerts J, Chen A, Dancey J . RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis. J Clin Oncol. 2019; 37(13):1102-1110. PMC: 6494357. DOI: 10.1200/JCO.18.01100. View

3.
Kuhl C, Alparslan Y, Schmoee J, Sequeira B, Keulers A, Brummendorf T . Validity of RECIST Version 1.1 for Response Assessment in Metastatic Cancer: A Prospective, Multireader Study. Radiology. 2018; 290(2):349-356. DOI: 10.1148/radiol.2018180648. View

4.
Sosna J . Is RECIST Version 1.1 Reliable for Tumor Response Assessment in Metastatic Cancer?. Radiology. 2018; 290(2):357-358. DOI: 10.1148/radiol.2018182179. View

5.
Winter K, Hofmann F, Thierfelder K, Holch J, Hesse N, Baumann A . Towards volumetric thresholds in RECIST 1.1: Therapeutic response assessment in hepatic metastases. Eur Radiol. 2018; 28(11):4839-4848. DOI: 10.1007/s00330-018-5424-0. View